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Abstract: We aimed to evaluate the expression of sarcosine metabolism-related proteins according to site of meta-
static breast cancer, and the clinical implications. Immunohistochemical staining for glycine N-methyltransferase 
(GNMT), sarcosine dehydrogenase (SARDH), and l-pipecolic acid oxidase (PIPOX) was performed on tissue micro-
arrays from 162 metastatic breast cancer (bone metastases = 47, brain metastases = 39, liver metastases = 
24, and lung metastases = 52). Sarcosine metabolism-related proteins showed variable expression with regard to 
metastatic sites. GNMT was expressed in brain and lung metastases, but not in bone and liver metastases (P = 
0.016). In view of the sarcosine metabolic phenotype, high sarcosine and intermediate type were only found in the 
brain and lung metastases, and low sarcosine type was observed more frequently in bone and lung metastases (P = 
0.047). By univariate analysis, PIPOX positivity was correlated with shorter overall survival (OS) (P = 0.031). In lung 
metastases, PIPOX positivity (P = 0.019) and stromal PIPOX positivity (P = 0.001) were associated with shorter OS. 
In conclusion, in metastatic breast cancer, sarcosine metabolism-related proteins are differently expressed accord-
ing to the metastatic site. Expression of GNMT and high sarcosine type are predominantly observed in brain and 
lung metastases.
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Introduction
Breast cancer is associated with high morbidity 
and mortality, largely due to distant metasta-
sis. Common metastatic sites of breast cancer 
include the lung, brain, liver, and bone [1, 2], 
and among these, brain and bone metastases 
have been thoroughly studied [3-8]. In general, 
reciprocal interaction between tumor cells and 
host tissue is the main mechanism of metasta-
sis, together with adhesion, proteolysis, inva-
sion, and angiogenesis [2, 9]. Because every 
single tumor shows a different metastatic pat-
tern, the ‘seed and soil’ hypothesis has been 
proposed as an explanation for how a specific 
tumor (seed) would survive in a specific visceral 
organ (soil) [10]. Similarly, metastatic breast 
cancer has different properties according to 
metastatic sites. In previous studies, young 
age, ER (estrogen receptor) negativity, prior 
lung metastasis, HER-2 (human epidermal 
growth factor-2) overexpression, EGFR (epider-
mal growth factor) overexpression, and basal 
subtype have been shown in brain metastases 
[5-7]. Lower histologic grade, ER positivity, ER 
positivity/PR negativity, strand growth pattern, 
and presence of fibrotic foci in invasive ductal 
carcinoma were found in bone metastases [4, 
11, 12]. Thus, different characteristics are 
associated with different metastatic sites. 
Sarcosine (N-methylglycine) is a non-proteino-
genic amino acid, synthesized from glycine 
metabolism. Glycine N-methyltransferase (GN- 
MT), sarcosine dehydrogenase (SARDH), and 
l-pipecolic acid oxidase (PIPOX) are the major 
enzymes in the sarcosine metabolism pathway. 
GNMT involves the transfer of a methyl group 
from S-adenosylmethionine (SAM) to glycine. 
Sarcosine-metabolizing enzymes, SARDH and 
PIPOX, convert sarcosine to glycine by oxidative 
demethylation [13]. Sarcosine is thought to be 
a potential oncometabolite rather than a non-
proteinogenic amino acid. In prostate cancer, 
sarcosine is a sensitive tumor biomarker and is 
associated with tumor progression and the 
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Table 1. Source, clone, and dilution of antibodies used in this study
Antibody Company Clone Dilution
Sarcosine metabolism-related
    GNMT Abcam, Cambridge, UK Polyclonal 1:100
    SARDH Abcam, Cambridge, UK Polyclonal 1:100
    PIPOX Abcam, Cambridge, UK Polyclonal 1:100
Molecular subtype-related
    ER Thermo Scientific, San Diego, CA, USA SP1 1:100
    PR DAKO, Glostrup, Denmark PgR 1:50
    HER-2 DAKO, Glostrup, Denmark Polyclonal 1:1500
    Ki-67 Abcam, Cambridge, UK MIB 1:1000
GNMT, glycine N-methyltransferase; SARDH, sarcosine dehydrogenase; PIPOX, l-pipecolic acid oxidase; ER, estrogen receptor; 
PR, progesterone receptor; and HER-2, human epidermal growth factor-2; ER, estrogen receptor; PR, progesterone receptor.
metastatic process [14, 15]. While increased 
sarcosine level has been studied in metastatic 
prostatic cancer [16], sarcosine metabolism in 
metastatic breast cancer has yet to be investi-
gated. As the tumor has been known to show 
different properties according to metastatic 
sites, evaluation of sarcosine metabolism-
related proteins in different metastatic sites is 
required. Hence, we aimed to evaluate the 
expression of sarcosine metabolism-related 
proteins according to site of metastatic breast 
cancer, and its clinical implication.
Materials and methods
Patient selection
Invasive primary breast cancer and metastatic 
breast cancer to distant organs (liver, lung, 
brain, and bone) were retrieved from data files 
of the Department of Pathology of Severance 
Hospital, Seoul, South Korea. Only patients 
with a diagnosis of invasive ductal carcinoma 
were included. A total of 169 cases were includ-
ed, and 49 cases consisted of paired primary 
and metastasis carcinomas. All slides were 
reviewed again and pathologic diagnoses were 
approved by two pathologists (JSK and WJ). The 
histological grade was assessed using the 
Nottingham grading system [17]. This study 
was approved by the Institutional Review Board 
of Severance Hospital.
Tissue microarray
On H&E-stained slides of tumors, a representa-
tive area was selected and a corresponding 
spot was marked on the surface of the paraffin 
block. Using a biopsy needle, the selected area 
was punched out and a 3-mm tissue core was 
placed into a 6 × 5 recipient block. Two tissue 
cores were extracted to minimize extraction 
bias. Each tissue core was assigned to a unique 
tissue microarray location number that was 
linked to a database containing other clinico-
pathologic data.
Immunohistochemistry
The antibodies used for immunohistochemistry 
in this study are shown in Table 1. Three-
micrometer paraffin sections were deparaf-
finized and rehydrated by xylene and alcohol 
solution. Immunohistochemistry was perform- 
ed using the Ventana Discovery XT automated 
stainer (Ventana Medical System, Tucson, AZ, 
USA). Antigen retrieval was performed using 
Cell Conditioning 1 (CC1; citrate buffer pH 6.0, 
Ventana Medical System). Appropriate positive 
and negative controls for immunohistochemis-
try were included.
Interpretation of immunohistochemical stain-
ing
All immunohistochemical markers were acce- 
ssed by light microscopy. Pathologic parame-
ters such as ER, PR, and HER-2 status were 
obtained from the patients’ pathologic reports. 
A cut-off value of 1% or more positively stained 
nuclei was used to define ER and PR positivity 
[18]. HER-2 staining was analyzed according to 
the American Society of Clinical Oncology 
(ASCO)/College of American Pathologists (CAP) 
guidelines using the following categories: 0 = 
no immunostaining; 1+ = weak incomplete 
membranous staining, less than 10% of tumor 
cells; 2+ = complete membranous staining, 
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Table 3. Expression of metabolism-related proteins in tumor cell compartments of breast cancer 
metastasis according to metastatic site 
Parameters Totaln = 162 (%)
Bone metastasis
n = 47 (%)
Brain metastasis
n = 39 (%)
Liver metastasis
n = 24 (%)
Lung metastasis
n = 52 (%) P-value
GNMT (T) 0.016
    Negative 153 (94.4) 47 (100.0) 37 (94.9) 24 (100.0) 45 (86.5)
    Positive 9 (5.6) 0 (0.0) 2 (5.1) 0 (0.0) 7 (13.5)
SARDH (T) 0.730
    Negative 158 (97.5) 45 (95.7) 38 (97.4) 24 (100.0) 51 (98.1)
    Positive 4 (2.5) 2 (4.3) 1 (2.8) 0 (0.0) 1 (1.9)
PIPOX (T) 0.069
    Negative 125 (77.2) 35 (74.5) 35 (89.5) 20 (83.3) 35 (67.3)
    Positive 37 (22.8) 12 (25.5) 4 (10.3) 4 (16.7) 17 (32.7)
PIPOX (S) 0.533
    Negative 152 (93.8) 43 (91.5) 36 (92.3) 24 (100.0) 49 (94.2)
    Positive 10 (6.2) 4 (8.5) 3 (7.7) 0 (0.0) 3 (5.8)
GNMT, glycine N-methyltransferase; SARDH, sarcosine dehydrogenase; PIPOX, l-pipecolic acid oxidase; T, tumor; S, stroma.
either uniform or weak in at least 10% of tumor 
cells; and 3+ = uniform intense membranous 
staining in at least 30% of tumor cells [19]. 
HER-2 immunostaining was considered posi-
tive when strong (3+) membranous staining 
was observed whereas cases with 0 to 1+ were 
regarded as negative. The cases showing 2+ 
HER-2 expression were evaluated for HER-2 
amplification by fluorescent in situ hybridization 
(FISH).
Immunohistochemical markers for GNMT, 
SARDH and PIPOX were accessed by light 
microscopy. Interpretation of immunohisto-
chemical staining was determined by multiply-
ing the proportion of stained cells (0% = 0, 
Table 2. Basal clinicopathologic characteristics of breast cancer metastasis according to metastatic 
site 
Parameters Totaln = 162 (%)
Bone metastasis
n = 47 (%)
Brain metastasis
n = 39 (%)
Liver metastasis
n = 24 (%)
Lung metastasis
n = 52 (%) P-value
Age (years) 0.022
    ≤ 50 81 (50.0) 27 (57.4) 17 (43.6) 6 (25.0) 31 (59.6)
    > 50 81 (50.0) 20 (42.6) 22 (56.4) 18 (75.0) 21 (40.4)
ER < 0.001
    Negative 69 (42.6) 8 (17.0) 26 (66.7) 6 (25.0) 29 (55.8)
    Positive 93 (57.4) 39 (83.0) 13 (33.3) 18 (75.0) 23 (44.2)
PR < 0.001
    Negative 109 (67.3) 23 (48.9) 38 (97.4) 12 (50.0) 36 (69.2)
    Positive 53 (32.7) 24 (51.1) 1 (2.6) 12 (50.0) 16 (30.8)
HER-2 0.017
    Negative 114 (70.4) 38 (80.9) 20 (51.3) 19 (79.2) 37 (71.2)
    Positive 48 (29.6) 9 (19.1) 19 (48.7) 5 (20.8) 15 (28.8)
Molecular subtype < 0.001
    Luminal A 67 (41.4) 33 (70.2) 4 (10.3) 15 (62.5) 15 (28.8)
    Luminal B 27 (16.7) 7 (14.9) 9 (23.1) 3 (12.5) 8 (15.4)
    HER-2 30 (18.5) 5 (10.6) 12 (30.8) 3 (12.5) 10 (19.2)
    TNBC 38 (23.5) 2 (4.3) 14 (35.9) 3 (12.5) 19 (36.5)
Patient death 53 (32.7) 23 (48.9) 11 (28.2) 7 (29.2) 12 (23.1) 0.040
ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor-2; TNBC, triple negative breast cancer.
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1-29% = 1, 30-100% = 2) with the intensity 
(negative = 0, weak = 1, moderate = 2, strong = 
3). The final scores of 0-1 and 2-6 were inter-
preted as negative (-) and positive (+), respec-
tively [20]. Ki-67 labeling indices (LI) were 
scored by counting the number of positively 
stained nuclei and expressed as a percentage 
of total tumor cells.
Tumor phenotype classification
In this study, we classified breast cancer phe-
notypes according to the immunohistochemis-
try results for ER, PR, HER-2 and Ki-67 and 
FISH results for HER-2 as follows [21]; Luminal 
A type: ER and/or PR positive and HER-2 nega-
tive and Ki-67 LI < 14%; Luminal B type: (HER-2 
negative) ER and/or PR positive and HER-2 neg-
ative and Ki-67 LI ≥ 14%, (HER-2 positive) ER 
and/or PR positive and HER-2 overexpressed 
and/or amplified; HER-2 overexpression type: 
ER and PR negative and HER-2 overexpressed 
and/or amplified; and TNBC type: ER, PR, and 
HER-2 negative.
Sarcosine metabolism phenotype
Based on the result of GNMT, SARDH, and 
PIPOX immunohistochemistry, the sarcosine 
metabolism phenotype was determined as fol-
lows; high sarcosine type: GNMT (+)/SARDH 
and PIPOX (-), low sarcosine type: GNMT (-)/
SARDH or PIPOX (+), intermediate sarcosine 
type: GNMT (+)/SARDH or PIPOX (+), and null 
type: GNMT (-)/SARDH and PIPOX (-).
Statistical analysis
Data were statistically processed using SPSS 
for Windows, version 12.0 (SPSS Inc., Chicago, 
IL, USA). Correlation analysis of immunostain-
ing results between primary breast cancer and 
metastatic breast cancer were calculated by 
McNemar test. Student’s t and Fisher’s exact 
tests were used to examine any differences in 
continuous and categorical variables, respec-
tively. A corrected p-value and the Bonferroni 
method were used for multiple comparisons. 
Statistical significance was assumed when P < 
0.05. Kaplan-Meier survival curves and log-
rank statistics were employed to evaluate time 
to tumor metastasis and time to survival. 
Multivariate regression analysis was performed 
using a Cox proportional hazards model.
Results
Patients’ clinicopathologic characteristics
Of 162 patients, 47 (29.0%) had bone metasta-
ses, 30 (18.5%) had brain metastases, 24 
(14.8%) had liver metastases, and 52 (32.1%) 
had lung metastases (Table 2). There was a 
higher frequency of ER-positive/PR-positive in 
bone and liver metastases (P < 0.001), and 
HER-2-positive in brain metastases (P = 0.017). 
Luminal A type was predominant in bone and 
liver metastases, and TNBC was predominant 
in brain and lung metastases (P < 0.001).
Expression of sarcosine metabolism-related 
proteins in metastatic breast cancer according 
to metastatic sites
When expression of sarcosine metabolism-
related protein was correlated with metastatic 
sites, GNMT expression was only observed in 
brain and lung metastases, not in bone and 
liver metastases (P = 0.016, Table 3 and Figure 
1). Based on sarcosine metabolism-related 
proteins expression, high sarcosine and inter-
mediate sarcosine type were found only in brain 
and lung metastases, and low sarcosine type 
was largely found in bone and lung metastases 
(P = 0.047, Table 4). In a set of 49-paired pri-
mary and metastatic tumors, the expression of 
sarcosine metabolism-related proteins was not 
statistically different (Table 5). 
Correlation between expression of sarcosine 
metabolism-related proteins and pathologic 
factors
Among sarcosine metabolism phenotypes, the 
high sarcosine type demonstrated higher Ki-67 
LI (P = 0.031). With regard to metastatic site, 
higher Ki-67 LI was associated with stromal 
PIPOX expression in bone metastases (P = 
0.031). In lung metastases, ER negativity was 
associated with PIPOX positivity (P = 0.009) 
and non-null type (P = 0.002, Figure 2). 
Impact of sarcosine metabolism-related pro-
tein expression on patient prognosis
PIPOX positivity (P = 0.031) and TNBC type (P = 
0.002) were associated with shorter OS by uni-
variate analysis (Table 6 and Figure 3). When 
risk factors for shorter OS in each metastatic 
site were assessed by univariate analysis, 
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Figure 1. Expression of sarcosine metabolism-related proteins in metastatic breast cancer according to metastatic 
sites. GNMT expression is only found in brain and lung metastases, and is absent in bone and liver metastases. 
PIPOX is highly expressed in in brain and lung metastases.
TNBC type (P < 0.001) in bone metastases, and 
PIPOX positivity (P = 0.019) and stromal PIPOX 
positivity (P = 0.001) in lung metastases, were 
significant risk factors (Figure 3).
Discussion
We examined the expression of sarcosine 
metabolism-related proteins in metastatic brea- 
st cancer according to the metastatic sites. 
GNMT was highly expressed in brain and lung 
metastases compared to the bone and liver 
metastases. Previous study has shown higher 
expression of sarcosine metabolism-related 
proteins in tumors with HER-2 molecular sub-
type [22]. Since brain and lung metastases 
contained a higher fraction of HER-2 type in the 
current study, higher expression of sarcosine 
metabolism-related proteins in brain and lung 
metastases was expected, and the result was 
concordant. Albeit there has been no previous 
study of sarcosine metabolism in metastatic 
breast cancer, a study of prostate cancer 
showed an association between increased sar-
Table 4. Sarcosine-related metabolic phenotypes of breast cancer metastasis according to metastatic 
site 
Parameters Totaln = 162 (%)
Bone metastasis
n = 47 (%)
Brain metastasis
n = 39 (%)
Liver metastasis
n = 24 (%)
Lung metastasis
n = 52 (%) p-value
Metabolic type 0.047
    High sarcosine type 5 (3.1) 0 (0.0) 1 (2.6) 0 (0.0) 4 (7.7)
    Low sarcosine type 36 (22.2) 13 (27.7) 4 (10.3) 4 (16.7) 15 (28.8)
    Intermediate sarcosine type 4 (2.5) 0 (0.0) 1 (2.6) 0 (0.0) 3 (5.8)
    Null type 117 (72.2) 34 (72.3) 33 (84.6) 20 (83.3) 30 (57.7)
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Figure 2. Correlation between pathologic factors and expression of sarcosine metabolism-related proteins.
Table 5. Correlation of expression of metabolism-related proteins between primary and metastatic 
breast cancer according to metastatic site
Parameters
Total Bone metastasis Brain metastasis Liver metastasis Lung metastasis
n = 49 (%) P-value n = 13 (%) P-value n = 9 (%) P-value n = 4 (%) P-value n = 23 (%) P-value
GNMT 1.000 1.000 N/A N/A 0.500
    (+) → (+) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
    (+) → (-) 1 (2.0) 1 (7.7) 0 (0.0) 0 (0.0) 0 (0.0)
    (-) → (+) 2 (4.1) 0 (0.0) 0 (0.0) 0 (0.0) 2 (8.7)
    (-) → (-) 46 (93.9) 12 (92.3) 9 (100.0) 4 (100.0) 21 (91.3)
SARDH 1.000 1.000 1.000 N/A 1.000
    (+) → (+) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
    (+) → (-) 1 (2.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (4.3)
    (-) → (+) 2 (4.1) 1 (7.7) 1 (11.1) 0 (0.0) 0 (0.0)
    (-) → (-) 46 (93.9) 12 (92.3) 8 (88.9) 4 (100.0) 22 (95.7)
PIPOX 1.000 0.375 0.500 N/A 1.000
    (+) → (+) 4 (8.2) 1 (7.7) 0 (0.0) 0 (0.0) 3 (13.0)
    (+) → (-) 8 (16.3) 4 (30.8) 0 (0.0) 0 (0.0) 4 (17.4)
    (-) → (+) 7 (14.3) 1 (7.7) 2 (22.2) 0 (0.0) 4 (17.4)
    (-) → (-) 30 (61.2) 7 (53.8) 7 (77.8) 4 (100.0) 12 (52.2)
(+) and (-) indicate protein expression levels that are positive and negative, respectively. Arrow indicates the change of protein expression from 
the primary tumor to the metastasis. GNMT, glycine N-methyltransferase; SARDH, sarcosine dehydrogenase; PIPOX, l-pipecolic acid oxidase; N/A, 
not available.
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Table 6. Univariate analysis of the impact of expression of metabolism-related proteins in metastatic breast cancers on overall survival by the 
log-rank test
Parameters
Total
n = 162 (%)
Bone metastasis
n = 47 (%)
Brain metastasis
n = 39 (%)
Liver metastasis
n = 24 (%)
Lung metastasis
n = 52 (%)
Mean survival
(95% CI) months P-value
Mean survival
(95% CI) months P-value
Mean survival
(95% CI) months P-value
Mean survival
(95% CI) months P-value
Mean survival
(95% CI) months P-value
GNMT (T) 0.310 N/A 0.473 N/A 0.407
    Negative 108 (93-122) N/A 109 (86-131) N/A 123 (95-151)
    Positive 132 (91-173) N/A 31 (7-55) N/A 144 (106-183)
SARDH (T) 0.795 0.769 N/A N/A N/A
    Negative 110 (96-124) 83 (62-104) N/A N/A N/A
    Positive 80 (51-110) 44 (43-45) N/A N/A N/A
PIPOX (T) 0.031 0.614 0.321 0.156 0.019
    Negative 118 (102-133) 87 (63-110) 110 (87-133) 90 (70-109) 145 (117-172)
    Positive 80 (55-106) 58 (41-75) 58 (16-100) 51 (26-76) 92 (53-132)
PIPOX (S) 0.194 N/A 0.690 N/A 0.001
   Negative 113 (98-127) N/A 108 (86-131) N/A 139 (115-162)
    Positive 51 (31-72) N/A 40 (27-52) N/A 37 (2-71)
Metabolic type 0.131 N/A N/A N/A N/A
    High sarcosine type 72 (48-96) N/A N/A N/A N/A
    Low sarcosine type 59 (46-72) N/A N/A N/A N/A
    Intermediate sarcosine type 128 (63-192) N/A N/A N/A N/A
    Null type 116 (100-132) N/A N/A N/A N/A
Molecular subtypes 0.002 < 0.001 0.081 N/A N/A
    Luminal A 105 (86-124) 84 (62-107) 55 (10-100) N/A N/A
    Luminal B 140 (111-170) 60 (26-93) 138 (112-164) N/A N/A
    HER-2 134 (109-158) 62 (47-77) 79 (60-97) N/A N/A
    TNBC 51 (38-64) 3 (2-4) 31 (22-39) N/A N/A
GNMT, glycine N-methyltransferase; SARDH, sarcosine dehydrogenase; PIPOX, l-pipecolic acid oxidase; T, tumor; S, stroma; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth 
factor-2; TNBC, triple negative breast cancer; N/A, not available; CI, confidence interval.
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cosine level and cancer progression. Benign 
prostate cells acquired an invasive phenotype 
with administration of sarcosine [13]. Further- 
more, patients with metastatic prostatic cancer 
revealed an elevated serum sarcosine level 
[16]. Therefore, it is considered that the sarco-
sine level is related to tumor progression in 
prostate cancer. We evaluated the expression 
level of GNMT, SARDH and PIPOX as surrogate 
markers of sarcosine level in the tissue from 
metastatic breast cancer. In a previous study, 
higher expression of GNMT and lower expres-
sion of SARDH and PIPOX was found in the tis-
sue of prostate cancer compared to the normal 
prostate [14]. Considering that GNMT is a sar-
cosine-generating enzyme, and SARDH and 
PIPOX are sarcosine-metabolizing enzymes, 
the expression levels of GNMT, SARDH, and 
PIPOX were well-correlated with the sarcosine 
level in the tissue [14]. In the current study, the 
high sarcosine type (GNMT (+)/SARDH and 
PIPOX (-)) was exclusively found in brain and 
lung metastases, and a higher sarcosine level 
in brain and lung metastases was suspected, 
but needs to be validated.
Khan et al. observed repression of tumor 
growth as a result of sarcosine inhibition [14]. 
Thus, it is expected that patients with meta-
static breast cancer harboring higher sarcosine 
metabolism-related protein expression would 
benefit from target therapy that inhibits the sar-
cosine metabolism pathway. In the present 
study, GNMT expression was elevated in brain 
and lung metastases, suggesting that sarco-
sine inhibition is a candidate therapeutic 
approach that should be validated in further 
study.
In conclusion, expression of sarcosine metabo-
lism-related proteins in metastatic breast can-
cer varied according to the metastatic site. 
Brain and lung metastases demonstrated high-
er expression of GNMT and a larger fraction of 
high-sarcosine type than other sites.
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